INDICATIONS AND USAGE
Gemfibrozil Tablets, USP are indicated as adjunctive therapy to diet for:
1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2,000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia.
2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms
of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce
LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol
levels in addition to elevated LDL-cholesterol and elevated triglycerides (see
WARNINGS, PRECAUTIONS
, and
CLINICAL PHARMACOLOGY
). The National Cholesterol Education Program has defined a serum HDL-cholesterol
value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease.
Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil.
In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant
increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER
DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED
INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN
AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED
DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH
ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO
NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID
ABNORMALITY.
In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at
baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and
placebo subgroups (see Table I).
The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body
weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior
to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises
in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should
be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma
triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen
therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be
considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods.
If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of
adhering to diet.